Attached files
| file | filename |
|---|---|
| EX-3.2 - EX-3.2 - GALECTIN THERAPEUTICS INC | d20778dex32.htm |
| EX-31.2 - EX-31.2 - GALECTIN THERAPEUTICS INC | d20778dex312.htm |
| EX-32.2 - EX-32.2 - GALECTIN THERAPEUTICS INC | d20778dex322.htm |
| EX-23.1 - EX-23.1 - GALECTIN THERAPEUTICS INC | d20778dex231.htm |
| EX-21.1 - EX-21.1 - GALECTIN THERAPEUTICS INC | d20778dex211.htm |
| EX-32.1 - EX-32.1 - GALECTIN THERAPEUTICS INC | d20778dex321.htm |
| EX-10.50 - EX-10.50 - GALECTIN THERAPEUTICS INC | d20778dex1050.htm |
| 10-K - FORM 10-K - GALECTIN THERAPEUTICS INC | d20778d10k.htm |
| EX-31.1 - EX-31.1 - GALECTIN THERAPEUTICS INC | d20778dex311.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statement Nos. 333-208674, 333-116629, 333-109893, 333-159247, 333-198070, 333-176306, and 333-176305 on Form S-8, and Registration Nos. 333-194747, 333-172849, 333-150898, 333-148911, 333-132459, 333-118907, 333-115118, 333-111650 and 333-109887 on Form S-3 of Galectin Therapeutics, Inc. of our report dated March 18, 2015, relating to our audit of the consolidated financial statements which appears in this Annual Report on Form 10-K of Galectin Therapeutics, Inc. for the year ended December 31, 2015.
/S/ RSM US LLP
Charlotte, North Carolina
March 15, 2016